RxDoctor Payments Data

Neil Richard, MD

Family Medicine · Westerville, OHNPI 1801865670

Payments from drug & device makers

$10,655in general payments, 2019–2025

Across 778 payments — averaging $13.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$1K
  • AbbVie$1K
  • Johnson & Johnson$960
  • AstraZeneca$862
  • Novo Nordisk$763
  • Pfizer$611
  • plus $5K from 49 others

What the payments were for

  • Food & beverage$10,51299%
  • Education$1421%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,655 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$41,679
Medicare patients
333
Services billed
690

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban524$230,337
OzempicSemaglutide82$85,691
MyrbetriqMirabegron118$37,842
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$35,680
JanuviaSitagliptin Phosphate68$35,342
XareltoRivaroxaban59$33,703
RexultiBrexpiprazole13$25,328
GemtesaVibegron84$21,943
FarxigaDapagliflozin Propanediol64$21,217
JardianceEmpagliflozin19$19,697
EntrestoSacubitril/Valsartan27$11,630
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$11,627
Atorvastatin Calcium724$11,546
LinzessLinaclotide20$11,260
Memantine Hcl180$11,049

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$611$230,337524 claims
Novo NordiskOzempic$763$85,69182 claims
GSKTrelegy Ellipta, Breo Ellipta$505$44,17981 claims
Astellas Pharma US IncMyrbetriq$400$37,842118 claims
MerckJanuvia$314$35,34268 claims
Johnson & JohnsonXarelto$960$33,70359 claims
AstraZenecaFarxiga, Breztri Aerosphere$862$32,84480 claims
Otsuka America Pharmaceutical, Inc.Rexulti$15$25,32813 claims
Sumitomo Pharma America, Inc.Gemtesa$18$21,94384 claims
Boehringer IngelheimJardiance$1,117$19,69719 claims
AbbVieLinzess, Lumigan$1,071$14,93533 claims
NovartisEntresto$268$11,63027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Westerville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →